Paolo Tarantino: Exploring IO and ADC Combinations at SITC25
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X by Society for Immunotherapy of Cancer, adding:
“The last decade has seen the rise of two new transformative anticancer treatment classes: IO and ADCs.
Their combination, either as separate agents or within ISACs, is pushing treatment boundaries even further.
Honored to have the chance to review this important topic at SITC25.”
Quoting Society for Immunotherapy of Cancer‘s post:
“SITC25 Science Preview:
Explore immunological dimensions of ADCs with Drs. Claire Friedman, Eli Lilly and Company, Alfred Zippelius, University Hospital Basel, Margaret K. Callahan, UConn Medicine, Paolo Tarantino, Dana-Farber, Harvard University, and Greg Thurber, University of Michigan.”
Watch the video attached to this post.
More posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023